OUR PIPELINE IS DESIGNED TO ADDRESS DISEASES WITH HIGH UNMET MEDICAL NEEDS

We paired our PLEX technology with drugs already approved by the U.S. FDA or innovative drug candidates

 

POLYPID'S PHASE 3 CLINICAL TRIALS:

  • D-PLEX100 – 302 – (NCT03558984) –  Open heart surgery

Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery.

Phase III, Prospective, Multinational, Multicenter, Randomized, Parallel Controlled, Two arms, Single Blind, Study to Assess the Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SOC) IV Prophylactic Antibiotic Treatment vs. SOC in Prevention of Post-Cardiac Surgery Sternal Infections.

First patient in: 19 February 2020

For more information, please visit clinicaltrials.gov:

https://clinicaltrials.gov/ct2/show/NCT02731573?term=D-PLEX&rank=1

  • D-PLEX100 – 311 – ( NCT04233424 ) – Abdominal / Colorectal surgery

Efficacy and Safety of D-PLEX in the Prevention of Abdominal Surgery Incision Infection Post Colorectal Surgery.

Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), compared to a SoC treated control arm, in prevention of post abdominal surgery incision infection.

First patient in: 24 June 2020

For more information, please visit clinicaltrials.gov:

https://www.clinicaltrials.gov/ct2/show/NCT04233424?term=PolyPid&draw=2&rank=4

  • D-PLEX -312 – (NCT04411199) – Abdominal/Colorectal surgery

Efficacy and Safety of D-PLEX in the Prevention of Abdominal Surgery Incision Infection Post Colorectal Surgery.

Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), compared to a SoC treated control arm, in prevention of post abdominal surgery incision infection.

First patient in Q4 2020

For more information, please visit clinicaltrials.gov:

https://www.clinicaltrials.gov/ct2/show/NCT04411199?term=PolyPid&draw=2&rank=3

Expanded Access Policy

For new medical products to be legally approved for use, pharmaceutical companies are required to evaluate the safety and effectiveness of the medical product in clinical trials and submit trial results to regulatory agencies. To participate in a clinical trial, patients must meet certain criteria. For those who meet the criteria to join a clinical trial, participation offers the chance to contribute to medical research that may benefit many others.

At the same time, we understand that there are seriously ill patients who will not be eligible for our clinical trials and may have high risk to experience an infection post a surgical intervention. In these circumstances, regulators/health authorities may grant permission for us to provide a treating physician with an investigational drug pre-approval.

It’s important to remember that investigational drugs have not yet received regulatory approval; therefore, their potential risks and benefits are not yet established. Doctors and patients should consider all possible benefits and risks when seeking expanded access to an investigational drug.

Surgeons seeking pre-approval access for patients should submit their requests to clinical@polypid.com.

 

For more information please access PolyPid Expanded Access Policy.

Phase 3 clinical trials D-PLEX100 efficacy D-PLEX100 efficacy Severe open fractures Perimplantitis

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >

D-PLEX100

Is designed to prevent the risk of surgical site infections in both bone and soft tissue through its cutting-edge, local, extended-release mechanism

Read More >

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >